Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis.

ABSTRACT:

Purpose

Intravitreal (IVT) injections of the anti-vascular endothelial growth factor (VEGF) agents aflibercept, bevacizumab, and ranibizumab are commonly prescribed to treat neovascular age-related macular degeneration (nAMD). Studies comparing inflammation rates in large populations of patients receiving these agents and the treatment of ocular inflammation post-IVT anti-VEGF injections are scarce. In this study, we compared rates of endophthalmitis claims (sterile and infectious) following IVT anti-VEGF injections to determine the risk factors associated with developing endophthalmitis, and examined the claims for subsequent treatment.

Patients and methods

This retrospective cohort study of USA claims data examined the risk of developing endophthalmitis following IVT injec

SUBMITTER: Kiss S 

PROVIDER: S-EPMC6124467 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature